Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

Background Talimogene laherparepvec (T-VEC), an oncolytic virus, was designed to selectively replicate in and lyse tumor cells, releasing tumor-derived antigen to stimulate a tumor-specific immune response.Methods In this phase II study in patients with unresectable stage IIIB–IV melanoma, we evalua...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Dirk Schadendorf, Ralf Gutzmer, Helen Gogas, Kate Liu, Josep Malvehy, Jean-Jacques Grob, Igor Samoylenko, Joseph J Sacco, Kevin S Gorski, Abraham Anderson, Cheryl A Pickett
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMJ Publishing Group 2021-03-01
Saila:	Journal for ImmunoTherapy of Cancer
Sarrera elektronikoa:	https://jitc.bmj.com/content/9/3/e001621.full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!